Histone acetylation-regulated FBXO11-dependent degradation of BLIMP-1 promotes lung injury Authors: Bangzhi Sui, Yingying Wang, Jie Liu Published: 2026 ABSTRACT BackgroundPediatric pneumonia, characterized by symptoms of fever and cough, presents certain challenges to clinical treatment due to a growing pathogen resistance and the difficulty of controlling inflammation in the immature pediatric immune system. Research on pediatric pneumonia has focused on the critical role of macrophage pyroptosis in pulmonary inflammation, with the aim of identifying novel therapeutic targets related to the modulation of inflammasome signaling pathways. The purpose of this study was to identify key genes associated with pediatric pneumonia and drugs that target these genes for the treatment of lung injury caused by the disease. Single-cell analysis revealed elevated F-box only protein 11 (FBXO11) expression in macrophages in patients with pediatric pneumonia.MethodsFirstly, the target genes in patients with pediatric pneumonia were analyzed via polymerase chain reaction (PCR) and single-cell data analysis. C57BL/6 mice were intranasally challenged with colony-forming units (CFU) of Streptococcus pneumoniae. Murine bone marrow-derived macrophages (BMDMs) or RAW264.7 cells were treated with pectolinarigenin and liposaccharide (LPS), and then pulsed with adenosine triphosphate (ATP).ResultsFBXO11 expression was upregulated in a pediatric pneumonia mice model, and small interfering RNA targeting F-box only protein 11 (si-FBXO11) alleviated lung injury in a mouse model of pediatric pneumonia. FBXO11 promoted macrophage pyroptosis in an in vitro pediatric pneumonia model. NOD-like receptor protein 3 (NLRP3) inhibitor treatment counteracted the propyroptotic effects of FBXO11 and B lymphocyte-induced maturation protein 1 (BLIMP-1) on macrophage pyroptosis in macrophages. FBXO11 suppressed BLIMP-1 expression and promoted its degradation in lung tissue from the pediatric pneumonia model. FBXO11 interlinked with BLIMP-1 and reduced BLIMP-1 expression and its ubiquitination. FBXO11 suppressed NLRP12 activity through the pyrin domain-containing 12 (NLRP12) promoter of the NOD-like receptor family at a BLIMP-1 binding site. Histone acetylation-regulated METTL3 enhanced FBXO11 messenger RNA (mRNA) stability through N(6)-methyladenosine (m6A) modification, thereby modulating pyroptosis. Pectolinarigenin bound to FBXO11 protein in macrophages and reduced macrophage pyroptosis in pediatric pneumonia.ConclusionsFBXO11 promotes macrophage pyroptosis by degrading BLIMP-1 and suppressing the NLRP12 and NLRP3 signaling pathway, thereby exacerbating lung injury in pediatric pneumonia. Targeting this pathway may exert a therapeutic effect. Notably, pectolinarigenin represents a promising candidate for mitigating macrophage pyroptosis in pediatric pneumonia and possibly other pediatric inflammatory diseases. Highlight box Key findings • F-box only protein 11 (FBXO11) promotes macrophage pyroptosis by degrading B lymphocyte-induced maturation protein 1 and suppressing the NOD-like receptor family pyrin domain-containing 12 and NOD-like receptor protein 3 signaling pathways, thereby exacerbating lung injury in pediatric pneumonia. What is known and what is new? • Because the inflammatory response in childhood pneumonia is difficult to control, clinical treatment presents certain challenges. • FBXO11 may be helpful in the treatment of childhood pneumonia. What is the implication, and what should change now? • This study supports the therapeutic potential of targeting FBXO11 for the treatment of pediatric pneumonia. • Pectolinarigenin may be a promising candidate for alleviating macrophage pyroptosis in pediatric pneumonia or other pediatric diseases. Introduction In recent years, the incidence of pediatric pneumonia has increased, making it one of the more common respiratory diseases in children (1). Epidemiological data indicate that pneumonia accounts for approximately 20% to 30% of all pediatric hospital admissions (2). Clinically, affected children often present with expectoration; chest tightness; cough; shortness of breath; dyspnea; thick, white sputum that is difficult to expectorate; wet rales on lung auscultation; and in severe cases, nasal flaring and lip cyanosis (3,4). Common pathogens associated with childhood pneumonia include parainfluenza virus and respiratory syncytial virus (5). Children are particularly susceptible to bronchopneumonia due to a combination of anatomical and physiological factors: their trachea and bronchi are narrower, alveolar development is immature, mucociliary clearance is weaker, mucus secretion is insufficient, and the lung interstitium is highly vascularized. These characteristics collectively impair the ability to clear pathogens effectively, leading to mucus retention and creating an environment favorable for bacterial proliferation (6,7). The onset and progression of pediatric pneumonia are associated with a variety of inflammatory cytokines (8). For one, the expression levels of certain cytokines may become altered during the disease course of pediatric pneumonia; for another, the abnormal expression of cytokines can influence the onset and prognosis of the disease. Additionally, during pediatric pneumonia, the levels of catalase and superoxide dismutase are insufficient, allowing hydrogen peroxide and superoxide anions to infiltrate respiratory epithelial cells (9-11). Subsequently, excessive oxidative stress induces damage to respiratory system cells, leading to the swelling and necrosis of respiratory epithelial cells (8). Cellular pyroptosis is a programmed cell death mechanism mediated primarily by caspase-mediated cleavage of the gasdermin D (GSDMD) protein upon recognition of specific ligands in the cytoplasm (12-14). The N-terminal fragment of GSDMD (GSDMD-N) forms pores in the cell membrane, leading to the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), which amplify inflammatory signaling and contribute to cell swelling and eventual rupture (15,16). The NLRC4 inflammasome plays a critical role in host defense against intracellular bacterial infections (17). During infection by pathogens such as Salmonella typhimurium, bacterial effector proteins delivered via the type III secretion system (T3SS) are sensed by NLR family apoptosis inhibitory protein (NAIP) receptors in the host cytosol (18). This recognition triggers NAIP-mediated activation of NLRC4, relieving its autoinhibition and promoting the assembly of an inflammasome complex with the adaptor protein ASC (19,20). Subsequently, caspase-1 is activated, leading to the maturation of IL-1β and IL-18, cleavage of GSDMD, and induction of pyroptosis (21). NLRP12 (NOD-like receptor family pyrin domain-containing 12) is a cytoplasmic pattern recognition receptor belonging to the NLR family and contributes to innate immune responses against pathogen invasion (22). It is predominantly expressed in myeloid cells—particularly neutrophils and eosinophils—and is most abundant in the liver (23). Although the full scope of its molecular functions remains unclear, NLRP12 has been shown to recognize various pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), initiating immune responses that enhance phagocyte activation and pathogen clearance (24,25). For instance, during influenza virus infection, NLRP12 facilitates neutrophil recruitment, influencing disease outcomes (26). F-box only protein 11 (FBXO11) plays a regulatory role in epithelial-mesenchymal transition (EMT) during cancer progression. Studies indicate that FBXO11 is widely expressed in both normal and pathological tissues, with notably elevated levels observed in injured tissues and highly invasive cancer cells (27). Its expression is closely associated with tumor metastasis and invasion, along with tissue repair processes (27). Furthermore, dysregulation of FBXO11 has been identified as a significant contributor to angiogenesis and cancer dissemination (28). Functionally, FBXO11 serves as the substrate recognition subunit of the SKP1-Cullin-F-box ubiquitin ligase complex, facilitating ubiquitin-mediated degradation of certain substrates and participating in the maintenance of genomic stability (29). Additionally, recent research suggests that FBXO11 is involved in the regulation of alternative splicing (30). Clinically, downregulation of FBXO11 has been linked to vitiligo, and somatic mutations in FBXO11 have been identified in diffuse large B-cell lymphoma, highlighting its diverse roles in human diseases (31). This study aimed to identify key genes associated with pediatric pneumonia and to identify drugs targeting these genes for the treatment of lung injury caused by this disease. We present this article in accordance with the ARRIVE and MDAR reporting checklists (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0467/rc). Methods Single-cell data, proteomics, and network informatics analyses The tissue-specific expression of FBXO11 in patients with pediatric pneumonia was evaluated via the Gene Expression Omnibus (GEO) series accession, GSE167363 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167363) (32), and proteomics and network informatics analyses were evaluated via GSE289556 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289556) (32). Single-cell data from patients with pneumonia were acquired from the China National GeneBank Sequence Archive dataset, CNP0002884 (14 samples). Changes in pulmonary immune cells were examined, including decreased alveolar macrophage counts and the infiltration of neutrophils and monocytes, as were changes in intestinal immune cells, including T-cell activation during the early and middle stages of viral infection and B-cell and Paneth-cell accumulation in the intestines. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Animal modeling of pediatric pneumonia in vivo, bronchoalveolar lavage fluid (BALF) detection, and measurement of lung wet:dry weight (W/D) ratio One-week-old neonatal C57BL/6 mice were intranasally challenged with 5 µL of phosphate-buffered saline (PBS) containing 2×106 colony-forming units (CFU) of Streptococcus pneumoniae. Age-matched control mice received an equivalent volume of sterile PBS alone. At 5 weeks postinfection, all mice were killed, and lung tissues were harvested under aseptic conditions. Lung homogenates were prepared and serially plated onto blood agar plates for bacterial load quantification. The agar plates were incubated at 37 °C with 5% CO2 for 24 h to enumerate viable pulmonary bacteria. Tracheal lavage was conducted three times per lung with 1 mL of precooled sterile PBS. The recovered lavage fluid was centrifuged at 2,000 rpm for 5 min at 4 °C. The cell pellet was resuspended in 0.5 mL of PBS, followed by total cell counting with a hemocytometer and cell differential analysis via Wright-Giemsa staining. Cell-free BALF supernatants were subjected to enzyme-linked immunosorbent assay (ELISA) to quantify proinflammatory cytokines. For the assessment of lung W/D ratio, freshly isolated lungs were weighed immediately to record wet weight after excess blood was blotted off. Subsequently, the tissues were dried in an oven at 80 °C until a stable constant dry weight was achieved. In vitro model of pediatric pneumonia Murine bone marrow-derived macrophages (BMDMs) were isolated from mice (5 to 6 weeks old, weighing 18–20 g). BMDMs were created through the application of L929 cell-conditioned medium in a manner described previously (13,33). BMDMs were treated with 500 ng/ml of liposaccharide (LPS) (cat. no. HY-D1056; MedChemExpress, Monmouth Junction, NJ, USA) for 4 h and then pulsed with adenosine triphosphate (ATP) (2 mM; cat. no. HY-B2176; MedChemExpress) for 30 min. RAW264.7 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS; Gibco) under a humidified 5% (v/v) CO2 atmosphere at 37 °C. RAW264.7 cells seeded in six-well plates were transfected with FBXO11 plasmid and small interfering RNA targeting F-box only protein 11 (si-FBXO11) plasmid via Lipofectamine 3000. After 48 h of transfection, RAW264.7 cells were treated with pectolinarigenin (100 µM) and 200 ng/ml of LPS for 4 h, and then pulsed with ATP (1 mM; Sigma-Aldrich, St. Louis, MO, USA) for 30 min. Histological examination and immunofluorescence, propidium iodide (PI) assay, cell viability assay, and LDH activity levels Tissue samples were fixed in 4% paraformaldehyde and subjected to hematoxylin-eosin (HE) staining, Masson trichrome staining, immunohistochemistry, and immunofluorescence as previously described (13,33). FBXO11 (cat. no. ab271002; 1:100; Abcam, Cambridge, UK) or NOD-like receptor protein 3 (NLRP3) (cat. no. ab283819; 1:100; Abcam) antibody were incubated at 4 °C overnight. These tissue samples were then incubated with corresponding secondary antibody (1:1000; Servicebio, Wuhan, China) for 1 h at 37 °C. Tissue samples were observed under an Axio Observer A1 fluorescence microscope (Zeiss, Oberkochen, Germany). PI, cell viability, and LDH activity levels were detected via the calcein/PI cell activity and cytotoxicity detection kit (cat. no. C2015S; Beyotime, Shanghai, China), Cell Counting Kit-8 (CCK-8) assay (cat. no. C0037; Beyotime), or LDH activity kit (cat. no. C0016; Beyotime) as described previously (34). Absorbance was measured at 450 nm with a Synergy H1 Multimode Microplate Reader (BioTek Instruments, Winooski, VT, USA). ELISA and flow cytometry For ELISA and flow cytometry, kits were purchased from Nanjing Jiancheng Bioengineering Research Institute (Nanjing China), including kits for IL-1β (cat. no. H002), IL-6 (cat. no. H007-1-1), and TNF-α (cat. no. H052-1); meanwhile, other kits were purchased from Beyotime, including for LDH (cat. no. C0016) and IFN-γ (cat. PI507). ELISA and flow cytometry were conducted according to the literature (35). Western blot and immunofluorescence assays Western blotting and immunofluorescence assay were performed in accordance with the literature (35). The membranes were incubated with FBXO11 (cat. no. ab271002; 1:1000; Abcam), NLRP3 (cat. no. ab283819; 1:1000; Abcam), NLRP12 (cat. no. 39296; 1:1000; Cell Signaling Technology, Danvers, MA, USA), caspase-1 (cat. no. ab207802; 1:1000; Abcam), GSDMD (cat. no. ab209845; 1:1000; Abcam), and β-actin (cat. no. GB15003-100; 1:1000; Servicebio) at 4 °C overnight. The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (GB23303 or GB23301; 1:5000; Servicebio) for 1 h at 37 °C. Protein was measured with an enhanced chemiluminescence (ECL) system (Beyotime) and analyzed via Image Lab 3.0 (Bio-Rad Laboratories, Hercules, CA, USA). Cells were blocked with PBS supplemented with 5% BSA for 2 h at room temperature, followed by incubation with the primary antibody overnight at 4 °C. Subsequently, cells were incubated with Alexa Fluor 488/555-conjugated secondary antibody for 2 h at room temperature and counterstained with 4’,6-diamidino-2-phenylindole (DAPI) for 15 min in the dark. As described previously (36), cells were then examined under electron microscopy with a H7650 transmission electron microscope (Hitachi, Tokyo, Japan) at 80 kV. Bioluminescence imaging A protocol was prepared before the study without registration. All experiments related to animals were approved by the Animal Care and Use Committee of Yijishan Hospital of Wannan Medical College (approval No. WNMC-AWE-2024184), in compliance with the institutional guidelines for the care and use of animals. The cHS4I-hBLIMP-1P-Luc transgenic mouse model was established according to previously described methods (37,38). Mice were anesthetized, and RAW264.7-h BLIMP-1-Luc was injected via the tail vein. The mice were then randomly assigned to the sham group (control), model group (pediatric pneumonia mice model), low group [12.5 mg/kg pectolinarigenin in pediatric pneumonia mice model, intraperitoneal (i.p.)], medium group (25 mg/kg pectolinarigenin in pediatric pneumonia mice model, i.p.), and high groups (50 mg/kg pectolinarigenin in pediatric pneumonia mice model, i.p.). The model and administration groups of mice were treated with LPS and then administered with the drug, as described in the Animal Experiment section. 24 hours after modeling and administration, the mice were killed and photographed. Bioluminescent imaging was performed with a QuickView3000 in vivo bioluminescence/fluorescence imaging system (Bio-Real Sciences, Shanghai, China). Statistical analysis P values lower than 0.05 were considered significant. Data are expressed as the mean ± standard deviation (SD), and statistical analyses were evaluated with one-way analysis of variance (ANOVA) followed by the Tukey post hoc test, and were visualized with GraphPad Prism 8 (Dotmatics, Boston, MA, USA). Results Upregulation of FBXO11 expression in a model of pediatric pneumonia The first aim of this study was to identify genes involved in the development and progression of pediatric pneumonia. Using gene expression microarray analysis, we discovered that FBXO11 expression was upregulated in a mouse model of pediatric pneumonia (Figure 1A). Immunohistochemistry, polymerase chain reaction (PCR), and immunofluorescence analyses further confirmed elevated FBXO11 expression and messenger RNA (mRNA) expression levels in the lung tissues of the pediatric pneumonia model (Figure 1B-1D). Additionally, stimulation with LPS and ATP induced both elevated FBXO11 protein and mRNA expression levels in BMDM cells (Figure 1E,1F). Upregulation of FBXO11 protein was also confirmed in the mouse model of pediatric pneumonia (Figure 1G). Overall, FBXO11 expression was upregulated in the pediatric pneumonia model. Upregulation of FBXO11 expression in the model of pediatric pneumonia. Heat map (A), FBXO11 expression levels from HE staining (B), FBXO11 mRNA expression levels (C), and FBXO11 expression levels from immunofluorescence (magnification: ×20) (D) in the mouse model of pediatric pneumonia. FBXO11 mRNA expression levels (E) and FBXO11 protein expression levels (F) in BMDMs treated with LPS and ATP. FBXO11 protein expression levels (G) in the lung tissue in a mouse model of pediatric pneumonia. *, P<0.05; **, P<0.01; ***, P<0.001 vs. sham or control group. ATP, adenosine triphosphate; BMDM, bone marrow-derived macrophage; DAPI, 4’,6-diamidino-2-phenylindole; FBXO11, F-box only protein 11; LPS, lipopolysaccharide; mRNA, messenger RNA; NLRP3, NLR family pyrin domain containing 3. FBXO11 expression in the macrophages of patients with pediatric pneumonia We next examined the role of FBXO11 in pediatric pneumonia using single-cell RNA sequencing. Analysis of patient samples revealed distinct FBXO11 expression patterns (Figure 2A). Specifically, FBXO11 was detected in macrophage (marked by CD36, CD68, CD83, etc.) of patients with pediatric pneumonia (Figure 2B). In contrast, no significant FBXO11 expression was observed in airway epithelial cells (AQP11 and SEC14L3), airway goblet cells (DUSP4, GALNT6, MUC20, and SPDEF), pulmonary alveolar type I cells (AGER, COL4A3, RTKN2, and SEMA3B), or type II alveolar cells (ABCA3, CXCR2, NKX2-1, and RUNX3) (Figure 2C-2F). Furthermore, flow cytometric analysis of serum samples indicated elevated levels of CD68 + FOXE1 and CD36 + FOXE1 in patients with pediatric pneumonia as compared to healthy controls (Figure 2G-2H). These findings indicate that FBXO11 expression is distinctly elevated in the macrophages of patients with pediatric pneumonia. FBXO11 expression in the macrophages of patients with pediatric pneumonia. Single-cell sequencing analysis of FBXO11 expression (A), including FBXO11-positive macrophages identified by CD38, CD68, CD83, CD163, and GPR34 markers (B). FBXO11-positive airway epithelial cells (C). FBXO11-positive airway goblet cells (D), FBXO11-positive pulmonary alveolar type I cells (E). FBXO11-positive pulmonary alveolar type II cells (F). Flow cytometric analysis of FBXO11-positive CD68+ cells (G) and FBXO11-positive CD36+ cells (H). ***, P<0.001, vs. control group. FBXO11, F-box only protein 11. Sh-FBXO11 reduced lung injury in a mouse model of pediatric pneumonia We further sought to clarify the pre-inflammation effect of FBXO11 in pediatric pneumonia. The experimental timeline is outlined in Figure 3A. In the mouse model of pediatric pneumonia, the sh-FBXO11 lentiviral vector significantly alleviated lung injury, as indicated by lower lung injury scores, a lower W/D ratio, and improved tissue pathology observed in H-E and Masson trichrome staining (Figure 3B,3C). sh-FBXO11 reduced lung injury in the mouse model of pediatric pneumonia. Flowchart of the experimental procedure (A). Lung injury score and W/D ratio (B). HE and Masson trichrome staining (C) (scale bar =100 µm). IL-1β, IL-6, TNF-α, and IFN-γ expression (D-G). The number of monocyte/macrophages (CD11b+Ly6G−Ly6C+ cells) (H). Arg1 mRNA (I). Nitric oxide production (J). Nos2 mRNA (K), FBXO11 expression in lung tissue (magnification: ×20) (L). *, P<0.05; **, P<0.01; ***, P<0.001 vs. negative control group. CD, cluster of differentiation; DAPI, 4’,6-diamidino-2-phenylindole; FBXO11, F-box only protein 11; HE, hematoxylin and eosin; i.p., intraperitoneal; IFN-γ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; mRNA, messenger RNA; sh-FBXO11, short hairpin RNA targeting FBXO11; TNF-α, tumor necrosis factor-α; W/D, wet:dry ratio. Furthermore, sh-FBXO11 treatment markedly lowered the levels of key inflammatory cytokines in lung tissues, including IL-1β, IL-6, TNF-α, and IFN-γ (Figure 3D-3G). It also reduced the population of monocytes/macrophages (CD11b+Ly6G−Ly6C+ cells), suppressed nitric oxide production, and downregulated the mRNA expression of Arg1 and Nos2 (Figure 3H-3K). Additionally, sh-FBXO11 lentiviral vector significantly inhibited F4/80+iNOS+ expression in lung tissues (Figure 3L). In summary, sh-FBXO11 ameliorated lung injury and suppressed macrophage-mediated inflammation in the mouse model of pediatric pneumonia. FBXO11 promoted microphage pyroptosis in the vitro model of pediatric pneumonia The mechanism by which FBXO11 regulates macrophage function in pediatric pneumonia remains unclear, but macrophage pyroptosis has been identified as an important pathogenic process in this disease (39,40). We therefore investigated the role of FBXO11 in regulating pyroptosis in macrophages in pediatric pneumonia. In LPS + ATP-stimulated RAW264.7 cells, FBXO11 plasmid transfection significantly inhibited cell growth, increased LDH release, and elevated the proportion of PI-positive cells (Figure 4A-4C). Conversely, si-FBXO11 plasmid enhanced cell growth while reducing LDH activity and PI-positive cell numbers (Figure 4A-4C). At the molecular level, FBXO11 overexpression increased N-GSDMD protein expression, whereas FBXO11 knockdown decreased it (Figure 4D). Consistent with these findings, sh-FBXO11 lentiviral vector also suppressed N-GSDMD expression in lung tissues of the mouse model (Figure 4E). FBXO11 promoted macrophage pyroptosis in an vitro model of pediatric pneumonia. Cell growth (A), LDH (B), PI-positive cell count (C), and GSDMD protein expression (D) in LPS + ATP-treated RAW264.7 cells. GSDMD protein expression (E) in a mouse model of pediatric pneumonia. Pyroptotic cell proportion in LPS + ATP-treated RAW264.7 cells (F) and in the mouse model of pediatric pneumonia (G). Lung injury score (H), W/D ratio (I), pyroptotic cell proportion (J), and HE staining (K) (scale bar =100 µm) in a mouse model of pediatric pneumonia treated by sh-FBXO11 + pyroptosis agonist (polyphyllin VI). Cell growth (L), LDH (M), PI-positive cell count (N), and pyroptotic cell proportion (O) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + pyroptosis inhibitor (Ac-YVAD-cmk). Pyroptotic cell proportion (P), cell growth (Q), LDH (R),PI-positive cell count (S) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + pyroptosis agonist (Ac-YVAD-cmk). *, P<0.05; **, P<0.01; ***, P<0.001. ATP, adenosine triphosphate; FBXO11, F-box only protein 11; GSDMD, gasdermin D; HE, hematoxylin-eosin; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; sh, short hairpin. Furthermore, FBXO11 plasmid increased the proportion of pyroptotic macrophages (caspase-1 and TUNEL double-positive cells), while si-FBXO11 plasmid reduced this proportion in LPS + ATP-treated RAW264.7 cells (Figure 4F). Similarly, sh-FBXO11 lentiviral vector decreased the proportion of pyroptotic macrophage levels in the mouse model of pediatric pneumonia (Figure 4G). To further confirm the functional role of FBXO11 in pyroptosis, we administered the pyroptosis agonist polyphyllin VI (20 mg/kg)in sh-FBXO11-treated mice. The agonist partially reversed the protective effects of FBXO11 knockdown, as evidenced by increased lung injury scores, W/D ratio, tissue damage (as indicated by HE staining), and elevated pyroptotic cell levels (Figure 4H-4K). In LPS + ATP-treated RAW264.7 cells, the pyroptosis inhibitor Ac-YVAD-cmk (40 µM) counteracted the propyroptotic effects of FBXO11 overexpression, promoting cell proliferation and inhibiting LDH release while lowering the abundance of PI-positive cells, and cells positive for caspase-1 and TUNEL (Figure 4L-4O).Conversely, the pyroptosis agonist polyphyllin VI (1 µM)exacerbated pyroptosis under FBXO11-knockdown conditions, further suppressing cell growth and increasing LDH activity, the rate of PI positivity, and the proportion of pyroptotic cells (Figure 4P-4S). Overall, these results suggest that macrophage pyroptosis is a key mechanism through which FBXO11 exerts its effects in pediatric pneumonia and that FBXO11 promotes macrophage pyroptosis within this disease environment. NLRP3 inhibitor reduced the effects of FBXO11 and BLIMP-1 on macrophage pyroptosis in the vitro model of pediatric pneumonia Given the established role of NLRP3 as a key mediator of pyroptosis in acute lung injury (41-43), we further investigated whether FBXO11 regulates macrophage pyroptosis through the NLRP3 pathway. In the presence of sh-FBXO11 lentiviral vector, administration of the NLRP3 agonist nigericin sodium salt (4 mg/kg) reversed the protective effects of FBXO11 knockdown. Specifically, it increased NLRP3, caspase-1, and N-GSDMD protein expression in lung tissue, elevated lung injury scores and W/D ratios, and exacerbated both lung tissue damage (as shown by HE staining) and pyroptotic cell death (cells positive for caspase-1 and TUNEL) in pediatric pneumonia mice (Figure 5A-5F). NLRP3 inhibitor reduced the effects of FBXO11 and BLIMP-1 on macrophage pyroptosis in an in vitro model of pediatric pneumonia. NLRP3, caspase-1, and GSDMD protein expression (A), lung injury score (B), W/D ratio (C), serum IL-1β level (D), HE staining (E) (scale bar =100 µm), and pyroptotic cell proportion (F) in a mouse model of pediatric pneumonia treated with sh-FBXO11 + NLRP3 agonist (nigericin sodium salt). NLRP3, caspase-1, and GSDMD protein expression (G), IL-1β level (H), cell growth (I), LDH level (J), PI-positive cell count (K), and pyroptotic cell proportion (L) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + NLRP3 inhibitor (CY-09; 5 µM). Pyroptotic cell proportion (M), NLRP3, caspase-1, and GSDMD protein expression (N), IL-1β level (O), cell growth (P), LDH level (Q), and PI-positive cell count (R) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + NLRP3 agonist (nigericin sodium salt). *, P<0.05; **, P<0.01; ***, P<0.001. ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; GSDMD, gasdermin D; HE, hematoxylin-eosin; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; NLRP3, NOD-like receptor protein 3; PI, propidium iodide; sh, short hairpin; W/D, wet:dry ratio. Conversely, in LPS + ATP-treated RAW264.7 cells overexpressing FBXO11, treatment with the NLRP3 inhibitor CY-09 (5 µM) attenuated pyroptosis. It enhanced cell proliferation; suppressed NLRP3, caspase-1, and N-GSDMD protein expression and IL-1β levels; and reduced LDH release, PI-positive cell count, and the proportion of pyroptotic cells (Figure 5G-5L). Furthermore, in LPS + ATP-treated RAW264.7 cells administered the si-FBXO11 plasmid, the NLRP3 agonist nigericin sodium salt (10 nM) restored pyroptotic activity. It upregulated NLRP3, caspase-1, and N-GSDMD protein expression and IL-1β secretion; inhibited cell proliferation; and increased LDH activity, the number of PI-positive cells, and pyroptotic cell levels (Figure 5M-5R). Overall FBXO11 promoted macrophage pyroptosis in the pediatric pneumonia model via activation of the NLRP3 pathway. FBXO11 suppressed BLIMP-1 and promoted degradation of BLIMP-1 In this study, we further sought to clarify the mechanism by which FBXO11 regulates the NLRP3-induced pyroptosis of macrophages in a pediatric pneumonia model using gene chip technology. Initial screening suggested that BLIMP-1 may be a potential downstream target of FBXO11 in this process (Figure 6A). In the mouse model of pediatric pneumonia, sh-FBXO11 lentiviral vector suppressed the expression of the FBXO11, BLIMP-1, NLRP4, NLRP3, and caspase-1 proteins, while it upregulated the expression of NLRP12 in lung tissue (Figure 6B). Similarly, in LPS + ATP-treated RAW264.7 cells, FBXO11 overexpression enhanced FBXO11, BLIMP-1, NLRP4, NLRP3, and caspase-1 protein expression, while it suppressed NLRP12 expression (Figure 6C). Conversely, FBXO11 knockdown produced the opposite effect (Figure 6C). Bioluminescence imaging also revealed that sh-FBXO11 lentiviral vector decreased BLIMP-1 expression in lung tissues of mice with pneumonia (Figure 6D). Immunofluorescence showed that sh-FBXO11 lentiviral vector suppressed FBXO11 and BLIMP-1 expression in these mice (Figure 6E). FBXO11 suppressed BLIMP-1 expression and promoted its degradation. Heat map by transcriptome (A) and FBXO11, BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (B) in a mouse model of pediatric pneumonia treated with sh-FBXO11. FBXO11, BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (C) in LPS + ATP-treated RAW264.7 cells administered FBXO11 or si-FBXO11, bioluminescence imaging (D) and immunofluorescence (magnification: ×20) (E) in a mouse model of pediatric pneumonia treated with sh-FBXO11. **, P<0.01; ***, P<0.001. ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; GSDMD, gasdermin D; LPS, lipopolysaccharide; NLRP12, NOD-like receptor family pyrin domain-containing 12; NLRP3, NOD-like receptor protein 3; sh, short hairpin; si, small interfering RNA. FBXO11 and BLIMP-1 suppressed NLRP12 activity in macrophages of the vitro model of pediatric pneumonia An additional aim of this study was to ascertain the role of BLIMP-1 in mediating the regulatory effects of FBXO11 on macrophage pyroptosis in pediatric pneumonia. In LPS + ATP-induced RAW264.7 cells, transfection with Si-BLIMP-1 plasmid, despite maintaining FBXO11 overexpression, suppressed the expression of the BLIMP-1, NLRP4, NLRP3, caspase-1, and N-GSDMD proteins; upregulated the expression of NLRP12; reduced IL-1β levels; and decreased LDH activity and PI-positive cell counts (Figure 7A-7F). FBXO11 and BLIMP-1 suppressed NLRP12 activity in the macrophages of an vitro model of pediatric pneumonia. BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (A), IL-1β level (B), cell growth (C), PI-positive cell count (D), and LDH level (E) in LPS + ATP-treated RAW264.7 cells treated with Si-FBXO11 + BLIMP-1. IL-1β level (F), BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (G), cell growth (H), PI-positive cell count (I), and LDH level (J) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + Si-BLIMP-1. BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (K), LDH level (L), PI-positive cell count (M), IL-1β level (N), cell growth (O), and proportion of pyroptotic cells (P) in LPS + ATP-treated RAW264.7 cells administered FBXO11 + NLRP12. NLRP12, NLRP3, caspase-1, and GSDMD protein expression (Q), proportion of pyroptotic cells (R), IL-1β level (S), cell growth (T), PI-positive cell count (U), and LDH level (V) in LPS + ATP-treated RAW264.7 cells administered si-FBXO11 + si-NLRP12. *, P<0.05; **, P<0.01; ***, P<0.001. ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; GSDMD, gasdermin D; IL-1β, interleukin-1 beta; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; NLRP12, NOD-like receptor family pyrin domain-containing 12; NLRP3, NOD-like receptor protein 3; PI, propidium iodide; Si, small interfering RNA. Furthermore, in LPS + ATP-treated RAW264.7 cells administered the si-FBXO11 plasmid, BLIMP-1 plasmid induced an increase in BLIMP-1, NLRP4, NLRP3, caspase-1/N-GSDMD protein expression; suppressed NLRP12 protein expression; increased IL-1β levels and the number of PI-positive cells; and promoted LDH activity (Figure 7G-7J). These results indicate that BLIMP-1 serves as a key downstream effector of FBXO11 in regulating macrophage pyroptosis. We further investigated the mechanism by which FBXO11 influences NLRP3-mediated pyroptosis via BLIMP-1 in the pediatric pneumonia model. In the presence of FBXO11 overexpression, transfection with NLRP12 plasmid suppressed BLIMP-1, NLRP4, NLRP3, caspase-1, and N-GSDMD protein expression; upregulated NLRP12; reduced IL-1β levels; and decreased LDH activity, PI-positive cell counts, and overall pyroptosis (Figure 7K-7P). Correspondingly, under FBXO11-knockdown conditions, transfection with si-NLRP12 plasmid elevated BLIMP-1, NLRP4, NLRP3, caspase-1, and N-GSDMD protein expression; suppressed NLRP12 protein expression, increased IL-1β levels, PI-positive cell counts, and pyroptosis levels; and promoted LDH activity (Figure 7Q-7V). FBXO11 interacted with BLIMP-1 to reduce BLIMP-1 ubiquitination The role of BLIMP-1 in mediating the effects of FBXO11 on mitochondria-dependent pyroptosis was investigated. In an in vitro model of pediatric pneumonia, FBXO11 upregulation induced the expression and BLIMP-1 (Figure 8A). Co-immunoprecipitation assays confirmed that FBXO11 physically interacts with BLIMP-1 under these conditions (Figure 8B). This interaction was further enhanced upon LPS + ATP stimulation (Figure 8C). Additionally, FBXO11 upregulation promoted ubiquitination of BLIMP-1 (Figure 8D), specifically enhancing its K48-linked ubiquitination in the pediatric pneumonia model (Figure 8E). FBXO11 interacted with BLIMP-1 to reduce BLIMP-1 ubiquitination. Immunofluorescence assay of FBXO11 protein-bound BLIMP-1 expression (magnification: ×40) (A), IP assay for FBXO11 protein-bound BLIMP-1 expression (B), IP assay for FBXO11 protein-bound BLIMP-1 expression under treatment with LPS + ATP (C), and of ubiquitination of BLIMP-1 (D,E). HDOCK was used to conduct molecular docking of BLIMP-1 and FBXO11 (F). IP assay for FBXO11 WT/Mut protein-bound BLIMP-1 protein and BLIMP-1 WT/Mut protein-bound FBXO11 protein expression (G). ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; IP, immunoprecipitation; LPS, lipopolysaccharide; Mut, mutant; WT, wild type. To further clarify how FBXO11 regulates BLIMP-1, we performed a three-dimensional structural modeling analysis, which revealed a direct interaction between FBXO11 and BLIMP-1. Specifically, residues Y23, I24, C51, I153, Y851, Q784, and G875 in BLIMP-1 formed hydrogen bonds with Y23, R48, Y54, E68, H876, and N897 in FBXO11, respectively (Figure 8F). Co-immunoprecipitation results demonstrated that wild-type (WT) FBXO11 bound to WT BLIMP-1, whereas WT FBXO11 did not interact with mutant (Mut) BLIMP-1, while Mut FBXO11 failed to bind WT BLIMP-1 (Figure 8G). FBXO11 suppressed NLRP12 activity through NLRP12 promoter via the BLIMP-1 binding site To determine whether BLIMP-1 regulates NLRP12 activity, we analyzed the base sequence of the NLRP12 promoter to identify potential transcription factor-binding sites (Figure 9A). Analysis of the putative BLIMP-1 binding site in NLRP12 revealed a sequence distinct from the previously identified consensus (Figure 9B). In RAW264.7 cells stimulated with LPS + ATP, FBXO11 and BLIMP-1 protein expression was induced, while that of NLRP12 was suppressed (Figure 9C). We generated a luciferase reporter vector driven by a 1412-bp fragment of the NLRP12 promoter (NLRP12-luc), along with a Mut version with a disrupted BLIMP-1 binding site (mutNLRP12-luc) (Figure 9D). RAW264.7 cells were transfected with NLRP12-luc, mutNLRP12-luc, or the pGL3 control vector and were either cotransfected with Flag-tagged BLIMP-1 (Flag-BLIMP-1) or stimulated with LPS (Figure 9E). Additional experiments involved cotransfection with Flag-BLIMP-1 or LPS stimulation alone (Figure 9F). In LPS + ATP-treated RAW264.7 cells, transfection with si-FBXO11 upregulated NLRP12 protein expression and reduced FBXO11 and BLIMP-1 levels (Figure 9G). Conversely, FBXO11 overexpression enhanced FBXO11 and BLIMP-1 expression while suppressing NLRP12 protein levels (Figure 9H). Taken together, these results demonstrate that FBXO11 suppresses NLRP12 activity by targeting the BLIMP-1 binding site within the NLRP12 promoter. FBXO11 suppressed NLRP12 activity through NLRP12 promoter via the BLIMP-1 binding site. Sequence of the human NLRP12 promoter region from −129 to −25 bp (A). BLIMP-1 binding site in the NLRP12 promoter with the BLIMP-1 DNA binding sequences (B). FBXO11, BLIMP-1, and NLRP12 protein expression in RAW264.7 cells were stimulated with LPS for 0, 1, 2, 4 and 8 hours (C). Luciferase reporter constructs generated to assess NLRP12 promoter luciferase activity (D,E). Luciferase activity level (F). FBXO11, BLIMP-1, and NLRP12 protein expression in RAW264.7 cells treated with si-FBXO11 + LPS + ATP (G). FBXO11, BLIMP-1, and NLRP12 protein expression in RAW264.7 cells treated with FBXO11 + LPS + ATP (H). *, P<0.05; **, P<0.01; ***, P<0.001. ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; LPS, lipopolysaccharide; NLRP12, NOD-like receptor family pyrin domain-containing 12; si, small interfering RNA. Histone acetylation-regulated METTL3 promoted FBXO11 mRNA stability through N(6)-methyladenosine (m6A) modification to regulate pyroptosis In models of pneumonia-induced acute lung injury, there is an increase in histamine acetylation and upregulation of the METTL3/m6A pathway (44-47), and it is well established that LPS induces histone acetylation in macrophages (48-50). In our study, we investigated the mechanism underlying the abnormal expression of FBXO11 in pediatric pneumonia, with a focus on the role of histone acetylation. We identified two histone acetylation sites in FBXO11 (Figure 10A). In RAW264.7 cells, LPS + ATP treatment upregulated both the mRNA and protein expression of H3K14ac (Figure 10B,10C) as well as FBXO11 protein expression (Figure 10D). Histone acetylation inhibitor (trichostatin A; 1.8 nM) reduced FBXO11 protein expression in LPS + ATP -induced RAW264.7 cells (Figure 10D). Thus, LPS + ATP induced FBXO11 histone acetylation in the model of pediatric pneumonia (Figure 10E). Histone acetylation-regulated METTL3 promoted FBXO11 mRNA stability through m6A modification to regulate pyroptosis. Histone acetylation sites (A), H3K14ac mRNA and protein expression (B,C), FBXO11 protein expression (D), and schematic of the experiment (E). ChIP-qPCR: METTL3 increased H3K4me3 levels (F). Methylation modification sites (G). FBXO11 mRNA expression (H). The stability of FBXO11 mRNA (I) and m6A sites in the 3’-UTR of WT and Mut FBXO11 (J). Luciferase activity level (K), m6A modification by WT and Mut FBXO11 (L), m6A modification by YTHDF1-3 (M-O), FBXO11 protein expression (P), and schematic of the experiment (Q). *, P<0.05; **, P<0.01; ***, P<0.001. ChIP-qPCR, chromatin immunoprecipitation followed by quantitative polymerase chain reaction; FBXO11, F-box only protein 11; m6A, N(6)-methyladenosine; METTL3, methyltransferase-like 3; mRNA, messenger ribonucleic acid; Mut, mutant; PRDX3, peroxiredoxin 3; UTR, untranslated region; WT, wild type. Moreover, chromatin immunoprecipitation (ChIP) assays were used to measure these epigenetic modifications, and the results from performing ChIP followed by quantitative PCR indicated that METTL3 increased H3K4me3 levels (Figure 10F). We next examined the mechanism by which METTL3 regulates FBXO11-mediated macrophage pyroptosis in pediatric pneumonia. Bioinformatic analysis suggested multiple methylation modification sites near FBXO11 (Figure 10G). Interestingly, the m6A-specific antibody IP significantly increased FBXO11 mRNA enrichment in RAW264.7 cells (Figure 10H). Additionally, si-METTL3 markedly reduced FBXO11 mRNA stability (Figure 10I). We further identified several m6A modification sites in the 3’-untranslated region (UTR) of FBXO11, with significant enrichment at sites 1–5 (Figure 10J). METTL3 overexpression reduced luciferase activity driven by WT FBXO11 3’-UTR but not by a Mut version (Figure 10K). The Mut FBXO11, with m6A sites 1–5 ablated, exhibited lower m6A modification levels compared to WT FBXO11 (Figure 10L). Moreover, YTHDF1 enhanced METTL3-induced m6A modification of WT FBXO11, while Mut of sites 1–5 diminished this effect (Figure 10M). However, YTHDF2 and YTHDF3 did not affect the METTL3-induced m6A modification of WT FBXO11 (Figure 10N,10O). METTL3 induced FBXO1 protein expression levels, and histone acetylation inhibitor (trichostatin A; 1.8 nM) reduced the effects of METTL3 on FBXO1 protein expression levels (Figure 10P). These results indicate that METTL3- mediated m6A modification increases FBXO11 stability in a YTHDF1-dependent manner. Moreover, LPS-induced histone acetylation-regulated METTL3 promoted FBXO11 mRNA stability through m6A modification to regulate pyroptosis (Figure 10Q), suggesting that, to some extent, pneumonia induced acute lung injury. Pectolinarigenin bound to FBXO11 protein in macrophages to reduce macrophage pyroptosis in the model of pediatric pneumonia We screened for precursor compounds capable of regulating FBXO11 and inhibiting its activity and identified pectolinarigenin as a promising candidate that showed no macrophage toxicity (Figure 11A,11B). Further experiments, including the analysis of its binding site, elucidated the mechanism by which pectolinarigenin targets FBXO11 in macrophages. Drug-protein interaction assays revealed that pectolinarigenin bound to FBXO11 and significantly enhanced the thermal stability of exogenous WT FBXO11. In contrast, it did not affect the thermal stability of Mut FBXO11, suggesting that residues Q-640, Q-667, and N-686 may be involved in the binding interaction (Figure 11C). Schematic representations of WT and Mut FBXO11 and are shown in Figure 11D. Pectolinarigenin influenced the thermophoretic behavior of FBXO11, increasing its melting temperature from approximately 55 to 60 °C upon binding (Figure 11E-11G). We further evaluated the therapeutic activity of pectolinarigenin in a mouse model of pediatric pneumonia. Administration of low (12.5 mg/kg), medium (25 mg/kg), and high (50 mg/kg) doses of pectolinarigenin suppressed the expression of FBXO11, BLIMP-1, NLRP4, NLRP3, caspase-1, and the N-GSDMD proteins in lung tissue while upregulating NLRP12 expression. This also reduced serum IL-1β levels, lowered lung injury scores, and W/D ratio while alleviating histopathological damage, as observed in HE-stained sections (Figure 11H-11L). Similarly, in BMDMs treated with LPS + ATP to induce pyroptosis, pectolinarigenin decreased IL-1β levels; downregulated FBXO11, BLIMP-1, NLRP4, NLRP3, caspase-1, and N-GSDMD protein expression; and promoted NLRP12 expression (Figure 11 M,11N). These results demonstrate that pectolinarigenin can bind to FBXO11 protein and suppress its activity, supporting its ability to mitigate macrophage pyroptosis in pediatric pneumonia. Pectolinarigenin bound to FBXO11 proteins in macrophages to reduce macrophage pyroptosis in a model of pediatric pneumonia. Schematic of the description (A). Cell growth (B). HDOCK was used to conduct molecular docking between pectolinarigenin and the FBXO11 protein (C). The thermal stability of WT FBXO11 and Mut FBXO11 plasmid after treatment with pectolinarigenin via CETSA (D,E). MST of FBXO11 incubated with pectolinarigenin (F). CETSA of FBXO11 incubated with pectolinarigenin (G); FBXO11, BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression (H), HE and Masson trichrome staining (I, scale bar =100 µm), lung injury score (J), W/D ratio (K), and serum IL-1β level (L) in a mouse model of pediatric pneumonia. FBXO11, BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression in vitro model of pediatric pneumonia (H), and serum IL-1β level (L) in LPS + ATP-treated BMDM cells. (M) IL-1β level. (N) FBXO11, BLIMP-1, NLRP12, NLRP3, caspase-1, and GSDMD protein expression in vitro model of pediatric pneumonia. **, P<0.01; ***, P<0.001 vs. sham or control group. #, P<0.05; ##, P<0.01, ###, P<0.001 vs. model group. ATP, adenosine triphosphate; BLIMP-1, B lymphocyte-induced maturation protein 1; BMDM, bone marrow-derived macrophage; CETSA, cellular thermal shift assay; FBXO11, F-box only protein 11; GSDMD, gasdermin D; HDOCK, hybrid docking; HE, hematoxylin-eosin; IL-1β, interleukin-1β; LPS, lipopolysaccharide; MST, microscale thermophoresis; Mut, mutant; NLRP12, NOD-like receptor family pyrin domain-containing 12; NLRP3, NOD-like receptor protein 3; W/D, wet:dry ratio; WT, wild type. Discussion Pediatric pneumonia is a common and easily acquired illness in young children, whose susceptibility is attributed to their structurally underdeveloped lungs and immature immune systems (51). The incidence peaks particularly during winter and spring, and common clinical manifestations include wheezing, fever, cough, and pulmonary rales (52). The disease often presents with abrupt onset and rapid progression, accompanied by pronounced and typical symptoms. Without timely and effective intervention, it may lead to severe respiratory dysfunction (53). Moreover, recurrent episodes can result in a range of complications, such as pulmonary heart disease, lung abscess, and respiratory failure, seriously endangering the lives of affected children (54,55). Interestingly, in our study, FBXO11 expression was upregulated in a pediatric pneumonia model, which is somewhat consistent with Jin et al.’s finding that Fbxo11 prevents podocyte injury (56). These findings suggest that FBXO11 may be actively involved in the pathogenesis of pediatric pneumonia and play an important role in its progression. Pediatric pneumonia arises primarily due to the pulmonary infections caused by pathogens such as bacteria and viruses and is associated with significant mortality (57). Excessive activation of inflammatory mediators can trigger a systemic inflammatory response, leading to clinical manifestations including hypotension, acute respiratory failure, and shock, all of which pose serious risks to patient health and survival (58). Lung injury in patients with pediatric pneumonia is closely linked to widespread activation of inflammatory cells and the subsequent release of inflammatory factors (59). In our study, FBXO11 was only expressed in the macrophages of patients with pediatric pneumonia, and in the in mouse model of pediatric pneumonia, sh-FBXO11 reduced lung injury and inflammation. Histone acetylation-regulated METTL3 promotes FBXO11 mRNA stability through m6A modification to regulate pyroptosis. Xu et al. found that the regulation of FBXO11 expression by tanshinone IIA alleviates IL-1β-induced chondrocyte apoptosis (60). These findings collectively suggest that FBXO11 is a macrophage-specific factor and a therapeutic target in pediatric pneumonia. Activated NLRP3 facilitates the proteolytic cleavage of procaspase-1 into its active form, caspase-1. Subsequently, caspase-1 cleaves both GSDMD and the precursor cytokines pro-IL-1β and pro-IL-18, generating the GSDMD-N as well as mature IL-1β and IL-18 (61). The GSDMD-N fragment then binds to phospholipids in the cell membrane and form pores, resulting in osmotic swelling, membrane rupture, and ultimately pyroptosis (62). Concurrently, the release of IL-1β and IL-18 amplifies the local inflammatory response (63). In our study, FBXO11 promoted macrophage pyroptosis in the in vitro model of pediatric pneumonia via NLRP3 activation. Jeon et al. reported that FBXO11 induces NLRP3 activation in response to bacterial toxins (64). Furthermore, these results found that FBXO11 accelerates NLRP3-mediated pyroptosis by promoting mitochondrial damage in macrophages. However, the details of the mechanism through which FBXO11 regulates mitochondrial injury remains unclear. The inflammasome is a multiprotein complex that serves as a critical component of the innate immune system (65). Among the various inflammasomes, NLRC4 (nucleotide-binding oligomerization domain-like receptor family CARD domain-containing 4) is particularly important as it is integral to detecting intracellular bacterial infections and figures prominently in the innate immune response (66). Upon infection of host cells by Salmonella typhimurium, the bacterium uses its T3SS to deliver rod protein (PrgJ) and flagellin (FliC) into the cytoplasm. These ligands interact with NAIPs, leading to their activation (67). This process induces the assembly of NAIP-NLRC4 inflammasomes, activates caspase-1, promotes the maturation of IL-1β and IL-18, and triggers GSDMD-mediated pyroptosis (68). In our study, NLRP3 inhibitor reduced the effects of FBXO11 and BLIMP-1 on macrophage pyroptosis in the vitro model of pediatric pneumonia. Jeon et al. reported that FBXO11 dampens the secretion of IL-1β after NLRP3 activation (64). Thus, our findings suggest that FBXO11 promotes mitochondrial damage in macrophage via BLIMP-1. As a member of the NOD-like pattern recognition receptor family, NLRP12 can detect pathogens and an array of intracellular stimuli, thereby modulating innate immune responses through multiple mechanisms (69). The immune effects triggered by NLRP12 vary depending on the pathogen involved (70). NLRP12 can both promote immune activation and suppress inflammatory responses (71). For instance, it facilitates the release of inflammasome-dependent cytokines such as IL-1β and IL-18, which help protect the host from pathogen infection (19). In our study, FBXO11 suppressed NLRP12 activity through NLRP12 promoter via the BLIMP-1 binding site. Shi et al. reported that downregulation of the BLIMP-1 axis exacerbates colitis-induced inflammation (72). Furthermore, by inhibiting NLRP12 activity through BLIMP-1, FBXO11 promotes mitochondrial damage in macrophages and the subsequent activation of the NLRP3 inflammasome. In our study, we used an in vivo S. pneumoniae infection model (involving a Gram-positive pathogen) and an in vitro model induced with the combination of LPS and ATP. S. pneumoniae primarily transmits signals through the recognition of PAMPs via Toll-like receptors 2/6 (TLR2/6), whereas LPS achieves activation via the toll-like receptor 4 (TLR4) signaling pathway. Compared with the responses induced by LPS from Gram-negative bacteria, those induced by Gram-positive bacteria typically activate different regulatory factors of the NLRP3 inflammasome. Therefore, there are certain limitations in directly extrapolating the LPS-induced pyroptosis mechanism to cases of pneumonia caused by S. pneumoniae. In future experiments, we will further explore and clarify this discrepancy. BLIMP-1 is a transcription factor involved in regulating T-lymphocyte differentiation (73). Basic research has demonstrated that BLIMP-1 contributes to the pathogenesis of diseases such as aplastic anemia, allergic rhinitis, and ulcerative colitis by modulating regulatory T cells and T helper 17 cells (74,75). Upregulation of BLIMP-1 expression can suppress BCL-6 expression and inhibit the differentiation of pro-inflammatory T cells (76). Therefore, modulating the BCL-6-BLIMP-1 balance influences T-cell subset differentiation and inflammatory responses (77). We found that FBXO11 suppressed BLIMP-1 expression and promoted the degradation of BLIMP-1 in the lung tissues of mice with pneumonia. FBXO11 interacted with BLIMP-1 to reduce BLIMP-1 ubiquitination. Horn et al. reported that FBXO11 regulates the developmental timing of BLIMP-1 and affects other life history traits (78). Additionally, FBXO11 enhances macrophage Blimp-1 activity by attenuating its ubiquitination. Naturally derived compounds have garnered significant interest in the field of drug discovery due to their favorable safety profiles, therapeutic efficacy, and widespread availability, which may make them valuable sources for novel drugs and drug leads (79,80). Pectolinarigenin, a natural flavonoid predominantly isolated from the traditional Chinese herb Cirsium japonicum, exhibits multiple biological activities—including antitumor, anti-inflammatory, and antioxidant effects—and thus has become a focus of recent research (81-83). In our study, we discovered that pectolinarigenin interacted with the FBXO11 protein in macrophages and reduced macrophage pyroptosis in the pediatric pneumonia model. These results suggest that pectolinarigenin binds directly to FBXO11 and may thus serve as an effective therapeutic agent for pediatric pneumonia. Conclusions Our study revealed a novel mechanism in pediatric pneumonia involving macrophage pyroptosis regulated by posttranslational modification. We found that FBXO11 alleviates lung injury by promoting the degradation of BLIMP-1, thereby suppressing macrophage pyroptosis through the inhibition of both NLRP12 and NLRP3 (Figure 12). These findings highlight the therapeutic potential of targeting FBXO11 for the treatment of pediatric pneumonia. Importantly, pectolinarigenin emerged as a promising candidate for alleviating macrophage pyroptosis in patients with pediatric pneumonia or other pediatric diseases. FBXO11-dependent degradation of BLIMP-1 alleviates lung injury in pediatric pneumonia through the reduction of macrophage pyroptosis via the suppression of NLRP12 and NLRP3. BLIMP-1, B lymphocyte-induced maturation protein 1; FBXO11, F-box only protein 11; GSDMD, gasdermin D; IL, interleukin; m6A, N(6)-methyladenosine; METTL3, methyltransferase-like 3; NLR, NOD-like receptor; NLRP12, NOD-like receptor family pyrin domain-containing 12; NLRP3, NOD-like receptor protein 3. Supplementary The article’s supplementary files as Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0467/prf